PURPOSE Nivolumab is standard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiogenic therapies, but its activity on brain metastases from ccRCC remains unknown, because these patients were excluded from pivotal studies. We aimed to assess the activity of nivolumab in this population. METHODS...
-
2019 (v1)Journal articleUploaded on: December 4, 2022
-
February 2021 (v1)Journal article
Background: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC).Methods: The National ESME-MBC observational cohort includes all consecutive patients newly...
Uploaded on: December 4, 2022 -
January 2020 (v1)Journal article
The aims of the present study were to describe treatment patterns and survival outcomes in patients with central nervous system metastases (CNSM) selected among metastatic breast cancer (MBC) patients included in a retrospective study from the Epidemiological Strategy and Medical Economics (ESME) MBC cohort.
Uploaded on: December 3, 2022 -
April 2020 (v1)Journal article
Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC).
Uploaded on: December 4, 2022 -
August 2023 (v1)Journal article
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing ( n = 72, cohort 1), HER2-low ( n = 74, cohort 2) and HER2 non-expressing ( n = 40, cohort 3)...
Uploaded on: November 25, 2023 -
July 24, 2023 (v1)Journal article
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing ( n = 72, cohort 1), HER2-low ( n = 74, cohort 2) and HER2 non-expressing ( n = 40, cohort 3)...
Uploaded on: October 11, 2023